期刊
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
卷 80, 期 3, 页码 523-543出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/MMBR.00069-15
关键词
-
类别
资金
- Portuguese Foundation for Science and Technology (FCT) [SFRH/BD/76440/2011]
- Center for Microbiome Informatics and Therapeutics
- NSF Expeditions in Computing Program as part of the Living Computing Project [1522074]
- Defense Threat Reduction Agency [HDTRA1-14-1-0007, HDTRA1-15-1-0050]
- National Institutes of Health [1DP2OD008435, 1P50GM098792, 1R01EB017755, 1R21AI12166901]
- U.S. Army Research Laboratory and U.S. Army Research Office, through the Institute for Soldier Nanotechnologies [W911NF-13-D-0001]
- FCT [UID/BIO/04469/2013]
- COMPETE 2020 [POCI-01-0145-FEDER-006684]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/76440/2011] Funding Source: FCT
Soon after their discovery in the early 20th century, bacteriophages were recognized to have great potential as antimicrobial agents, a potential that has yet to be fully realized. The nascent field of phage therapy was adversely affected by inadequately controlled trials and the discovery of antibiotics. Although the study of phages as anti-infective agents slowed, phages played an important role in the development of molecular biology. In recent years, the increase in multidrug-resistant bacteria has renewed interest in the use of phages as antimicrobial agents. With the wide array of possibilities offered by genetic engineering, these bacterial viruses are being modified to precisely control and detect bacteria and to serve as new sources of antibacterials. In applications that go beyond their antimicrobial activity, phages are also being developed as vehicles for drug delivery and vaccines, as well as for the assembly of new materials. This review highlights advances in techniques used to engineer phages for all of these purposes and discusses existing challenges and opportunities for future work.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据